Diversify Wealth Management LLC Has $2.20 Million Stock Holdings in Astrazeneca Plc $AZN

Diversify Wealth Management LLC grew its holdings in Astrazeneca Plc (NYSE:AZN) by 184.0% during the 1st quarter, Holdings Channel reports. The firm owned 11,855 shares of the company’s stock after purchasing an additional 7,681 shares during the period. Diversify Wealth Management LLC’s holdings in Astrazeneca were worth $2,196,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in AZN. Triumph Capital Management acquired a new position in shares of Astrazeneca during the 3rd quarter worth about $25,000. MV Capital Management Inc. acquired a new stake in shares of Astrazeneca during the fourth quarter worth $26,000. Mascoma Wealth Management LLC acquired a new stake in shares of Astrazeneca in the 1st quarter valued at about $26,000. Bangor Savings Bank lifted its position in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Finally, Eagle Bay Advisors LLC acquired a new position in Astrazeneca during the fourth quarter valued at approximately $30,000. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Trading Down 1.1%

AZN opened at $169.79 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The company has a fifty day moving average of $183.38 and a 200-day moving average of $188.67. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The stock has a market cap of $263.32 billion, a PE ratio of 25.49, a price-to-earnings-growth ratio of 1.39 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. On average, sell-side analysts predict that Astrazeneca Plc will post 10.28 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AZN shares. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. HSBC cut Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and an average target price of $211.00.

Key Stories Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca struck an exclusive global license deal for the lung-cancer drug Zegfrovy, a move that could strengthen its oncology pipeline and long-term growth prospects. Article Title
• Positive Sentiment: UBS reiterated a Buy rating ahead of second-quarter results, saying AstraZeneca should deliver solid earnings and revenue. Article Title
• Neutral Sentiment: Analysts from both the U.S. and U.K. cited a mixed setup, with some optimism on near-term results but limited scope for AstraZeneca to raise full-year guidance. Article Title
• Negative Sentiment: HSBC downgraded AstraZeneca to Hold and cut its price target after the Wainua Phase 3 failure, saying the setback weakens the stock’s bull case. Article Title

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.